Press Releases

Datatrak International, Inc., a worldwide Software-as-a-Service (“SaaS”) provider and innovation leader of cloud-based technologies for the life sciences industry, announces a new partnership with Renibus Therapeutics, Inc. for their COVID-19 clinical trial. Renibus Therapeutics, Inc., headquartered in Dallas, Texas, is targeting unmet medical needs. Renibus is actively developing drugs intended for the prevention of acute kidney injury and the treatment of chronic kidne

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced positive topline data from the pivotal ADAPT trial of efgartigimod. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Responders a

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced new preclinical results for PXL770, the lead molecule in the Company’s adenosine monophosphate-activated protein kinase (AMPK) platform. PXL770, a direct AMPK activator, was evaluated in a rodent NASH model in combination with other key agents in development, including an FXR agonist (obetic

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, today announces that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1. In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is cur

AGC Biologics , an international contract development and manufacturing company (CDMO) for biopharmaceuticals, has announced its collaboration with Takara Bio , who will work together to fight COVID-19 by working together on a prophylactic Develop a DNA vaccine, with AGC Biologics producing the intermediate plasmid DNA for vaccination. "We are doing hard work in our fight against COVID-19," said Koichi Nakao , CEO of Takara Bio . "We are grateful for the support of AG

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an exclusive distribution agreement with Medusa19 Limited (“Medusa19”) for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen. Avacta recently announced a partnership with Cytiva (formerly GE Healthcare Life Sciences) to develop a saliva-based rapid antigen test to indicate whether a person has the COVID-19

Agilex Biolabs, Australia's largest specialist bioanalytical laboratory for biotech clinical trials, is presenting the Australian Advantage including the world's most attractive rebate on clinical trials costs, at BIO Korea 2020. The presentation by Kurt Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D, PGCM) Director, Immunoassay at Agilex Biolabs, also detailed how well the Australian clinical trials industry had managed during the COVID-19 crisis with most sites, CROs, and

Aetion has signed a research collaboration agreement with the U.S. Food and Drug Administration (FDA) to use real-world data to advance the understanding of and response to coronavirus disease (COVID-19). The research will support FDA objectives to explore the natural history of the disease, as well as treatment and diagnostic patterns, by facilitating the use of relevant, novel data sources and analyzing these data according to well-established principles. "The FDA i

BC Platforms and Kaiser Permanente today announced they are winners of the 2020 Microsoft Health Innovation Award in the Reimagine Health Category for enabling a unique way of pairing clinical and genomic data on the same platform to advance precision medicine capabilities. BC Platforms and Kaiser Permanente collaborated using Microsoft’s Azure cloud platform to safely and securely integrate data from multiple research centers into a single virtual biobank framework.

Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has initiated a Phase 1b/2 clinical study in patients undergoing bunionectomy of HTX-034, Heron's next-generation product for the treatment of postoperative pain. The study initiation follows clearance from the U.S. Food and Drug Administration (FDA) of Heron&#